

**FLASCO:***The Voice of Oncology in Florida***FLASCO
2015-2016
Board of Directors**

Michael Diaz MD
President

Barry Berman MD
Vice President

Hank Hill MD
Secretary

Richard McDonough MD
Treasurer

Alan Marks MD
Immediate Past President

Pooja Advani MD
Gary Bowers MD
Delmarie Butler RN
Robert Cassell MD PhD
Alan Collin MD
Gerardo Colon-Otero MD
Craig Deligdisch MD
Ana Espinosa DNP MBA RN OCN
Steven Fein MD
Rui Fernandes MD DMD
Karen Fields MD
Laura Finn, MD
Laura Freedman MD
Morganna Freeman-Keller DO
Larry Gandle MD
Jorge J. Garcia PharmD
Thomas George MD FACP
Shelly Glenn
Lucio Gordan MD
Terry Gruchow PAC
Ardeshir Hakam MD
William Harrer MD
Eric Harris DO
William Harwin MD
Nalini Hasija MD
Randal Henderson MD MBA
John Hiemenz MD
Maen Hussein MD
Mohammad Jahanzeb MD
Kun Jiang MD
Waseem Khan MD
Kapisthalm Kumar MD
Richard Levine MD
Thomas Marsland MD
Shahla Masood MD
Howard McLeod PhD
Tarek Mekhail MD
Joseph Mignone MD
Daniel Morris MD
Pareshkumar Patel MD
Luis Racz MD
Alice Rhoton-Vlasak MD
Steven Roshon MD
Carolyn Runowicz MD
Edgardo Santos MD
Michael Scott MD MBA
Clifford Selsky MD PhD
Christine Simone MD
Jason Starr DO
Abhisek Swaika MBBS
Winston Tan MD
Scott Tetreault MD
Samuel Thomas MD
Teri Walls

**Dorothy Phillips
Executive Director**

**YOU, your Colleagues, and All Oncology Healthcare Professionals
are Invited to Attend the**

FLASCO 2015 FALL SESSION

November 6-7, 2015

**Tampa Airport Marriott Hotel
George J. Bean Parkway | Tampa, FL 33607**



KEY NOTE SPEAKER

Daniel F. Hayes, President Elect of the American Society of Clinical Oncology (ASCO). Dr. Hayes is the Stuart B. Padnos Professor of Breast Cancer Research and the Clinical Director of the Breast Oncology Program in the University of Michigan Comprehensive Cancer Center. He is an expert in the field of breast cancer, and in addition to his clinical expertise he directs breast cancer research, especially in regard to new treatments, and development, evaluation and clinical use of tumor markers. He was a charter member of ASCO's Tumor Marker Guideline Expert Panel, which he has co-chaired for the past three years.

Dr. Hayes will share what is happening on the national front on issues ranging from the development of *Biomarkers* to ASCO's 2016 strategic plans.

**This conference is proudly
co-sponsored by the
following Companies:**

**someday is today****The Medical Educator Consortium**

DESCRIPTION OF ACTIVITY

The Florida Society of Clinical Oncology is hosting a two day meeting designed for medical oncologists, hematologists, radiation oncologists, oncology nurses, nurse practitioners, pharmacists, physician assistants, residents and fellows that manage health care for cancer patients. This conference will provide an emphasis on multidisciplinary collaboration among all professional health care teams with dynamic educational tracks that focus on specific driven topics addressing the current and future changes in the landscape of cancer care.

The 2015 Fall meeting will center on the multi-disciplinary presentations and case studies in lung, head & neck, prostate, and urology malignancies which include the collaboration of top clinicians, as well as up-to-date information on investigational drugs, future pathways in genomics, management of toxicities, support of care, and immunotherapy in current cancer care. Additional sessions include information on Affordable Care Act and PTSD, post traumatic stress disorder, that address issues concerning the oncology patient

Thursday, November 5, 2015

7:00pm–9:00pm Non CME *Diamond & Board Member Event*

Friday, November 6, 2015

7:00am–9:00am Non CME *Diamond & Board Member Event*

9:00am–12:00pm **FLASCO Board Meeting**

12:00pm–2:00pm Non CME *Diamond & Board Member Event*

2:00pm–4:00pm **FLASCO Board & Platinum Corporate Meetings**

6:00pm–7:30pm **Reception/Visit Exhibits Cash Bar Available**

7:30pm–9:30pm **DINNER & PROGRAM**
Welcome & Opening Remarks Michael Diaz, MD, FLASCO President -Fellow Travel Awards: ASH & ASTRO
Keynote Speaker Daniel F. Hayes, ASCO President Elect An ASCO Update

Saturday, November 7, 2015

6:30am–8:00am **Registration/Breakfast/Visit Exhibitors**

8:00am–8:30am *Opening Remarks & Supporter Recognition*

8:30am–9:30am **General Session**
Biomarkers Daniel F. Hayes, MD American Society of Clinical Oncology (ASCO) President Elect

9:30am–10:15am **Break/Visit Exhibitors**

	Multi-Disciplinary	Pharmacy	Nursing	Nurse Navigator
10:15am–11:45am	<i>New Developments in Lung Cancer</i> Michael E. Menefee MD Mayo Clinic Jacksonville Nishan Techekmedyan, MD Fellow, Moffitt Cancer Center	<i>Reducing Medication Errors in Oncology</i> Dina Dumercy PharmD BCPS BCOP Memorial Regional Hospital Ray Bailey RPh Florida Cancer Specialists	<i>Managing Common Toxicities in: Anti-EGFR, ALK and ROS-1 Inhibitor Therapies</i> Ofelia Betancourt MSN ARNP OCN Memorial Cancer Institute	<i>Nurse Navigator Credentialing & Lay Patient Navigator Certifications</i> Dara Leichter RN MHA OCN CBCN P L Biomedical
	<i>Head & Neck Cancer: an Innovative Approach to Treatment</i> Frank Civantos MD University of Miami Roi Dagan MD MS University of Florida Brian Hunis MD Memorial Cancer Institute	<i>Investigational Drugs: Present & Future Pathways in Genomics & Drug Delivery</i> Jennifer Mourafetis PharmD MBA BCPS Memorial Regional Hospital Amanda Brahim PhramD BCOP BCPS BCACP Cleveland Clinic	<i>Chemotherapy Induced Neuropathic Pain</i> Mayra Lima ARNP MSN FNP-C Memorial West Breast Cancer Center	<i>The Affordable Care Act & Oncology Patients</i> Evania Nichols MBA Janssen Biotech,

	LUNCH & PROGRAM	Lunch & Program
11:45am–1:30pm	Alan Marks, MD Immediate President of FLASCO - Moderator David Charles MD Alliance for Patient Access <i>Biosimilars & its Effect on Personalized Medicine</i>	<i>Cancer Survivorship</i> Mary Ann Morgan PHD RN Moffitt Cancer Center <i>Invited</i>

	Multi-Disciplinary	Pharmacy	Nursing	Nurse Navigator
1:30pm–3:00pm	<i>Implications of Inherited Breast Cancer over the Care Continuum</i> Hank Hill, MD St. Vincent Surgical Associates Jason Starr DO Cancer Specialists of North Florida Tuya Pal MD FACMG Moffitt Cancer Center– USF Brendan Prendergast, MD Space Coast Cancer Center	<i>On Our Way to a New Chapter; US Pharmacopeia <USP> 800</i> Jorge Garcia PharmD MS MBA Memorial Cancer Institute Melody Chang RPh MBA BCOP Florida Cancer Specialists	<i>Immunology in Malignancy</i> Jeanelle King PA-C Mount Sinai Comprehensive Cancer Center	<i>CoC's Distress Screening Guidelines: Post Traumatic Stress Disorder and the Oncology Patient</i> Michele Rosenthal Your Life After Trauma, LLC
	<i>Future Treatments of Prostate Cancer</i> David Thiel MD Mayo Clinic Randal Henderson MD University of Florida Winston Tan MD Mayo Clinic Abhisek Swaika MBBS Mayo Clinic		<i>The Nurses Role in Caring for Patients with Hematologic Malignancies: A case study in caring for the APL patient</i> Emily Bennett RN BSN OCN MD Anderson Cancer Center	<i>Metrics & Navigation</i> Susan Scherer RN BSN OCN RN Cancer Guides LLC
3:00pm–3:30pm	<i>Closing Remarks</i>			

CONFERENCE OBJECTIVES

Upon completion of the conference you will be able to:

- 1) Understand the latest developments on cancer biomarkers in the treatment of patients
- 2) Recognize the signaling pathways within the tumor microenvironment involved in cell proliferation, survival, invasion, metastasis, and immunosuppression
- 3) Identify and treat the cancer patient with PTSD, post traumatic stress disorder
- 4) Manage therapy complications and common toxicities with Anti-EGFR, ALK, and ROS-1 inhibitors
- 5) Apply novel concepts in supportive care of chemotherapy induced neuropathy
- 6) Identify future pathways in genomic & drug delivery
- 7) To be more familiar with indication and toxicities of immunotherapy for lung cancer, prostate cancer and melanoma

CONFERENCE OUTCOME MEASURES:

Participants should be able to apply the knowledge acquired during this conference to improve their competence, performance, and/or patient outcomes in the daily treatment of their patients. To measure attendees perceptions of these gains, they will complete an evaluation form at the end of the conference.

ACCREDITATION STATEMENTS

Physicians: The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical Educator Consortium designates this live activity for a maximum of 6 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The

Medical Educator Consortium and Florida Society of Clinical Oncology. The Medical Educator Consortium is accredited by the ACCME to provide continuing medical education for physicians.

Pharmacists: This program is not yet approved for CE. CE has been applied for from Memorial Hospital. Total number of approved credits is yet to be determined. FLASCO maintains responsibility for this program.

Nurses: This program is not yet approved for CEU credit. CE has been applied for from the Southern Florida Chapter of The Leukemia & Lymphoma Society under provider number 50-12996, expiration date 10/31/16. Total number of approved credits is yet to be determined. FLASCO maintains responsibility for this program.

Disclosure Statement: The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.

2015 Corporate Members As of 07/06/2015

FLASCO acknowledges the following companies as FLASCO Corporate Members

Diamond

Alexion Pharmaceuticals
Astellas Pharma
Bayer Oncology
Bristol-Myers Squibb
Celgene
Genetech BioOncology
Janssen Diagnostics, LLC
Lilly Oncology
Novartis
Onyx Pharmaceuticals an Amgen Subsidiary
Pfizer
Sandoz
Takeda Oncology
Teva Oncology

Platinum

Amgen
Biodesix
Boehringer Ingelheim
Dendreon
Eisai, Inc
Foundation Medicine
Insys Therapeutics
Janssen, a Pharmaceutical Company of J&J
Medivation Field Solutions
Merck
Myriad Genetics
nanoString Technologies
Oncology Supply/ION Solutions
Pharmacyclis
Rosetta Genomics
Sanofi
Seattle Genetics
Taiho Oncology, Inc.

Gold

Gilead Sciences
Incyte

Silver

AstraZeneca
Genomic Health
Helsinn
IPSEN BioPharmaceuticals
Spectrum Pharmaceuticals
TESARO

HOTEL RESERVATIONS

A block of rooms has been reserved at the
Tampa Airport Marriott Hotel
4200 George J. Bean
Parkway | Tampa, Florida 33607
Please make your RESERVATIONS by calling 813-879-5151 or follow this [link](#).

Book your group rate for Florida Society of Clinical Oncology

Mention the Florida Society of Clinical Oncology for meeting rate of \$167/inclusive per night.



DEADLINE - The Marriott Orlando World Center Hotel has requested that all reservations be made prior to **September 25, 2015**. After that date, reservations will only be accepted on a space available and rate available basis.

FLASCO MISSION STATEMENT

The Florida Society of Clinical Oncology is a statewide non-profit organization committed to facilitating and promoting multidisciplinary efforts to improve patient care in Florida by:

- Fostering access to quality cancer care to the citizens of Florida.
- Assisting the cancer practitioners in providing the most cost effective quality care for their patients.
- Acting as an advocate for Florida cancer patients and their families.
- Coordinating the dissemination of information and providing an opportunity for oncologists, physicians, and other health care professionals to network and exchange information on cancer care.

REGISTRATION

There are no registration fees for FLASCO Members. If you are not a member of FLASCO, there is a registration fee of \$250 for physicians. **Reminder:** To keep your complimentary membership active and in good standing, FLASCO members are encouraged to participate in at least one FLASCO event prior to December 31, 2016, or make a minimum contribution of \$50 to the FLASCO Foundation, Inc.

FLASCO reserves the right to alter this program without prior notice. Speakers and agenda are subject to change.

FLORIDA SOCIETY OF CLINICAL ONCOLOGY

10022 Water Works Lane | Riverview, FL | 33578

Phone: 813.677.0246 ext. 102 | Fax: 813.677.0559

Email: Dorothy.Green@FLASCO.org